期刊名称：EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
 Aims and scope
The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
a compound that is interesting and new in some basic or fundamental way, or
methods that are original in some basic sense, or
a highly unexpected outcome, or
conclusions that are scientifically novel in some basic or fundamental sense.
Straightforward descriptive data in drug utilization will only be considered if more than one geographical area is studied and if a scientific hypothesis is tested or an intervention carried out. Descriptive data in drug utilization can however be quite useful in a more local setting. Again, if conceptually new methods, analysis, or ways of reasoning are involved, this would elicit greater interest from the international scientific community. In such a case, we would welcome submission to the EJCP and evaluate the paper according to standard procedures.
The Journal also accepts review articles on various topics related to drug action in man. Debate on controversial issues is also encouraged, usually in the form of a letter to the editor that comments on a paper published in the Journal. Case reports on new findings or a new understanding of a mechanism of action should usually also be submitted in the form of a letter to the editor.
Instructions to Authors
Manuscript submission
Manuscript Submission
Permissions
Online Submission
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities ?tacitly or explicitly ?at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online?on the right and upload all of your manuscript files following the instructions given on the screen.
Instructions to Authors
0031-6970.pdf
Editorial Board
Editorial Board
Coordinating Editor
Rune Dahlqvist
Division of Clinical Pharmacology
University Hospital
90185 Ume?BR>Sweden
E-mail: rune.Dahlqvist@pharm.umu.se
Editorial Secretary
Aina Mattsson
E-mail: Aina.Mattsson@pharm.umu.se
Fax: +46 90 120 430
Managing Editors
N. Bateman, Edinburgh
U. Fuhr, Cologne
E.J. Sanz, La Laguna
Reviews Editor
U. Klotz, Stuttgart
Advisory Editors
J. Azuma, Osaka
J. Benitez, Badajoz
J.S. Bertino Jr, Albany
M. Bonati, Milan
A.R. Boobis, London
C.J. van Boxtel, Amsterdam
A.M. Breckenridge, Liverpool
I. Choonara, Derby
F. Chung, London
U. Christians, Denver
M.L. Dahl, Uppsala
L. de Jong-van den Berg, Groningen
V. Dolzan, Ljubljana
J. Feely, Dublin
R. Ferner, Birmingham
A. Figueras, Barcelona
A. Gaedigk, Kansas City
S. Garattini, Milan
A. Grahnén, Uppsala
W.E. Haefeli, Heidelberg
S. Hägg, Linköping
G. Hempel, Münster
N. Holford, Auckland
K. Hoppu, Helsinki
A. Jetter, Zurich
J. Kirchheiner, Ulm
M.H. Lader, London
J.R. Laporte, Barcelona
D.R. Matthews, Oxford
J. Miners, Adelaide
T. Mjörndal, Ume?BR>N. Montanaro, Bologna
J.L. Montastruc, Toulouse
P.J. Neuvonen, Helsinki
R. Norrby, Lund
M. Orme, Liverpool
O. Pelkonen, Oulu
R. Raschetti, Roma
F. Sjöqvist, Huddinge
O. Spigset, Trondheim
P. Thürmann, Wuppertal
T. Tomson, Stockholm
R.K. Verbeeck, Brussels
E. Vinge, Lund
T.P.G.M. de Vries, Amsterdam
T. Walley, Liverpool
W.S. Waring, Edinburgh
M. Wehling, Mannheim
N.J. White, Oxford
K.W. Woodhouse, Cardiff
?Yasar, Ankara
H.H. Zhou, Changsha
|
